|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-8-7
|
|
pubmed:abstractText |
We present results of 2 similarly designed but separate phase 2 studies involving single-agent lenalidomide (CC-5013, Revlimid) in a total of 68 patients with symptomatic myelofibrosis with myeloid metaplasia (MMM). Protocol treatment consisted of oral lenalidomide at 10 mg/d (5 mg/d if baseline platelet count < 100 x 10(9)/L) for 3 to 4 months with a plan to continue treatment for either 3 or 24 additional months, in case of response. Overall response rates were 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia. Response in anemia was deemed impressive in 8 patients whose hemoglobin level normalized from a baseline of either transfusion dependency or hemoglobin level lower than 100 g/L. Additional treatment effects in these patients included resolution of leukoerythroblastosis (4 patients), a decrease in medullary fibrosis and angiogenesis (2 patients), and del(5)(q13q33) cytogenetic remission accompanied by a reduction in JAK2(V617F) mutation burden (1 patient). Grade 3 or 4 adverse events included neutropenia (31%) and thrombocytopenia (19%). We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:AllredJacob BJB,
pubmed-author:ByrneCatrionaC,
pubmed-author:CortesJorgeJ,
pubmed-author:GilesFrancisF,
pubmed-author:HoganWilliam JWJ,
pubmed-author:JonesDanD,
pubmed-author:KantarjianHagop MHM,
pubmed-author:KetterlingRhett PRP,
pubmed-author:LashoTerra LTL,
pubmed-author:LitzowMark RMR,
pubmed-author:McClureRebecca FRF,
pubmed-author:MesaRuben ARA,
pubmed-author:TefferiAyalewA,
pubmed-author:ThomasDeborahD,
pubmed-author:VerstovsekSrdanS,
pubmed-author:ZeldisJerome BJB
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1158-64
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16609064-Administration, Oral,
pubmed-meshheading:16609064-Adult,
pubmed-meshheading:16609064-Aged,
pubmed-meshheading:16609064-Anemia,
pubmed-meshheading:16609064-Anemia, Myelophthisic,
pubmed-meshheading:16609064-Female,
pubmed-meshheading:16609064-Hemoglobins,
pubmed-meshheading:16609064-Humans,
pubmed-meshheading:16609064-Janus Kinase 2,
pubmed-meshheading:16609064-Male,
pubmed-meshheading:16609064-Neovascularization, Pathologic,
pubmed-meshheading:16609064-Neutropenia,
pubmed-meshheading:16609064-Platelet Count,
pubmed-meshheading:16609064-Point Mutation,
pubmed-meshheading:16609064-Primary Myelofibrosis,
pubmed-meshheading:16609064-Protein-Tyrosine Kinases,
pubmed-meshheading:16609064-Proto-Oncogene Proteins,
pubmed-meshheading:16609064-Remission Induction,
pubmed-meshheading:16609064-Sequence Deletion,
pubmed-meshheading:16609064-Splenomegaly,
pubmed-meshheading:16609064-Thalidomide,
pubmed-meshheading:16609064-Thrombocytopenia,
pubmed-meshheading:16609064-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
|
pubmed:affiliation |
Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. tefferi.ayalew@mayo.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
